🔗 Share this article

As the US undertakes historic adjustments to its vaccination guidelines, one figure has surfaced somewhat surprisingly: Høeg, an American of Danish descent sports medicine doctor and public health researcher who rose to prominence by casting doubt on Covid shots in the global health crisis and has focused upon alleged fatalities following Covid vaccination in her short time at the US Food and Drug Administration (FDA).

Scheduled Changes to Childhood Vaccine Program

Public health authorities had intended to reveal sweeping changes to the pediatric immunization program in December, synchronizing the US with the Danish national calendar, it is understood – a major change that would put the US at odds with many the international standard with insufficient data for public health gain. The planned update has been postponed until the next year.

Rather than the top vaccines chief, Dr. Høeg is set to present at the gathering. She was recently named interim head of the FDA’s drug evaluation center, the fifth individual to run the division this calendar year.

Consolidating Power at the Agency

This interim role might represent a tighter collaboration between the pharmaceutical and biologics divisions as Høeg and Dr. Prasad consolidate power at the FDA – and it signals a greater focus upon reevaluating already-approved vaccines at the FDA.

Dr. Høeg has frequently advocated for ending specific childhood vaccine recommendations in the US in order to be more similar to Denmark's approach, a society with universal health coverage and a population roughly the population of Wisconsin’s.

In her initial public appearances, she has continued to focus on vaccination policy – typically the domain of Prasad, chief of the FDA’s CBER – rather than pharmaceutical oversight.

Doubts Over Qualifications

The appointee has little discernible experience in medication creation, regulation or management, which has been typical for former heads of the biologics center. She has served at the FDA as a key advisor to the agency head and CBER since earlier this year.

“She doesn’t seem to have the necessary background” for running the pharmaceutical oversight division, stated Dr. Jonathan Howard. “She has not conducted a randomized controlled trial. She lacks experience in running a large organization. She is not an expert in pharmaceutical oversight.”

Previous directors of CBER would “be deeply familiar with regulatory frameworks and the underlying principles of medication creation”, noted Janet Woodcock. “Clearly, she lacks the type of experience that previous people who led CBER have had.”

The drug center has an vast portfolio at the FDA, she emphasized.

“The public just pays attention on the novel medication approvals, but the generic program approves a multitude of off-brand pharmaceuticals. There is also a biosimilars division, over-the-counter program and so forth, and all of those must be looked after,” she noted. “The responsibility you overlook, that is precisely what that I always told people is going to bite you.”

Furthermore, a major management component to the job, which supervises over 5,000 employees. “It is a massive leadership role, if you execute it properly,” Woodcock concluded.

Official Statement and Disputed Programs

When asked about inquiries about Høeg’s credentials and whether this selection signifies greater collaboration among FDA leaders on vaccines, a press secretary responded that the “questions stem from inaccurate assumptions”.

“Her resume matches the responsibilities of her job,” the representative said, citing the time Høeg spent counseling the agency head on “pharmaceutical safety and regulatory science, including predictive safety algorithms and immunization monitoring”.

In her interim role, Høeg takes over the agency head's recently launched priority voucher program, a controversial expedited therapy clearance system that apparently concerned her preceding directors. “How are these drugs being picked for this voucher program? Who makes the calls?” Howard said. “There’s a lot of secrecy happening at the FDA right now.”

In general, he said, “the FDA looks to be trending towards less stringent regulations of pharmaceuticals, aside from vaccines.”

Public History on Immunizations

Regarding vaccines, Høeg has a more established, if troubling, track record, Howard observe. She authored a analysis using non-validated public submissions to determine the incidence of heart inflammation after COVID-19 immunization. She advised the Florida top health official Joseph Ladapo, who reportedly have altered data to imply COVID-19 vaccines are pose a greater threat than they are.

Included in her “policy goals” for the incoming administration featured changing guidelines for novel immunizations and ending “optional” immunizations, she said post-election on a online show. At the agency, Dr. Høeg has allegedly suggested preventing young men from getting Covid vaccines.

“She is an complete true believer who commences with her conclusions and reverse-engineers to retrofit the data in a very deceptive, untruthful way,” Howard stated.

Taking Control and a “Campaign of Retribution”

Høeg joined other contrarians, {like|